Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis

CardioVascular and Interventional Radiology

Volumn 35, Issue 5, 2012, Pages 1119-1128

  Malagari, Katerina ^a   Pomoni, Mary ^a   Moschouris, Hippocrates ^b   Bouma, Evanthia ^a   Koskinas, John ^a   Stefaniotou, Aspasia ^a   Marinis, Athanasios ^b   Kelekis, Alexios ^a   Alexopoulou, Efthymia ^a   Chatziioannou, Achilles ^a   Chatzimichael, Katerina ^a   Dourakis, Spyridon ^a   Kelekis, Nikolaos ^a   Rizos, Spyros ^b   Kelekis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

Doxorubicin loaded drug eluting beads; Drug eluting beads; Embolization in unresectable hepatocellular carcinoma; Hepatocellular carcinoma; Survival; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; SORAFENIB;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH CLASSIFICATION; CHOLECYSTITIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG ELUTING BEAD; FEMALE; GALLBLADDER DISEASE; GALLBLADDER THICKENING; HUMAN; IMPLANT; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; POSTEMBOLIZATION SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SYNDROME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84867578516     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0394-0     Document Type: Article

References (38)

1. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171
2. Llovet JM, Real MI, Montana X et al (2002) Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359(9319):1734-1739
3. Lammer J, Malagari K, Vogl T et al (2010) PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41-52
4. Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474-481
5. Poon RN, Tso WK, Pang RWC et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5(9):1100-1108
6. Kettenbach J, Stadler A, Katzler I et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31(3):468-476
7. Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolisation of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB) Results of an open label study of 62 patients. Cardiovasc Intervent Radiol 31(2):269-280
8. TM. Abdom Imaging 33(5):512-519
9. Reyes DK, Vossen JA, Kamel IR et al (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15(6):526-532
10. Poggi G, Quaretti P, Minoia C et al (2008) Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28(6B):3835-3842
11. Biondi M, Fusco S, Lewis AL et al (2012) New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead™ for use in transarterial chemoembolization (TACE). J Biomater Sci Polym Ed 23(1-4):333-354
12. Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC Bead(™): results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34(4):774-785
13. National Cancer Institute (2003) Common Terminology Criteria for Adverse Events, version 3.0. National Cancer Institute, Bethesda, Maryland
14. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (2003) Notice of Modifications March 31, 2003-June 10, 2003
15. Bruix J, Sherman M, Llovet JM et al (2001) EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-430
16. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30(1):6-25
17. Vogl TJ, Naguib NN, Nour-Eldin NE et al (2009) Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 72(3):116-505
18. Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664):614-616
19. Raoul JL, Sangro B, Forner A et al (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37(3):212-220
20. O'Suilleabhain CB, Poon RTP, Yong JL et al (2003) Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90(3):325-331
21. Takayasu K, Arii S, Ikai I et al (2006) Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131(2):461-469
22. Maeda S, Fujiyama S, Tanaka M et al (2002) Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 23(3):202-210
23. Hayashi K, Ina H, Tezuka M et al (2007) Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc Intervent Radiol 30(6):1144-1155
24. Lencioni R, Cioni D, Crocetti L et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961-967
25. Montorsi M, Santambrogio R, Bianchi P et al (2005) Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg 9(1):62-68
26. Omata M, Tateishi R, Yoshida H et al (2004) Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 127(5 Suppl 1):159-166
27. Lam VW, Ng KK, Chok KS et al (2008) Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 207(1):20-29
28. Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 19(10):1490-1496
29. Burrel M, Reig M, Forner A, et al. (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DC Beads. Implications for clinical practice and trial design. J Hepatol. doi: 10.1016/j.jhep.2012.01.008
30. Lee JK, Chung YH, Song BC et al (2002) Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 17(1):52-58
31. Grieco A, Marcoccia S, Miele L et al (2003) Transarterial hemoembolisation (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 50(49):207-212
32. Memon K, Kulik L, Lewandowski RJ et al (2011) Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141(2):526-535
33. Kwok PC, Lam TW, Chan SC et al (2000) A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 32(6):955-964
34. Ernst O, Sergent G, Mizrahi D et al (1999) Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 172(1):59-64
35. Herber SC, Otto G, Schneider J et al (2008) Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol 190(4):1035-1042
36. Venook AP, Stagg RJ, Lewis BJ et al (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8(6):1108-1114
37. Lencioni R, De Baere Th, Burrel M, et al. (2011) Transcatheter treatment of hepatocellular carcinoma with doxorubicin loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. doi: 10.1007/s00270-011-0287-7
38. Brown DB, Nikolic B, Covey AM et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287-294